Asthma Clinical Trial
Official title:
A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8154 Following Single and Multiple Ascending Dose Administration in Healthy Subjects.
This study is a Phase 1, first in human (FiH) study, consisting of 3 parts (Part 1, Part 2, and Part 3) in healthy male and female participants of non-childbearing potential, performed at a single study center. Part 1 of this study will be a randomized, single-blind, placebo-controlled, single ascending dose (SAD) in healthy male and female participants of non-childbearing potential. Six dose levels of AZD8154 are planned to be investigated. Depending on emerging data, 1 to 2 additional dose levels may be added at the discretion of the Sponsor. Furthermore, one dose level will be repeated using the same formulation of AZD8154 but with a larger particle size (Part 1 only). Part 2 of this study will be a single cohort, open-label, 2-period, study to compare a single inhaled dose of AZD8154 (small particle size) nebuliser suspension with a single IV dose of AZD8154. Part 3 will be a single blind placebo controlled, multiple ascending doses (MAD) sequential design study in healthy male and/or female subjects of non childbearing potential conducted at a single center. Part 3:Three (3) inhaled dose levels of AZD8154 are planned to be investigated. Depending on the emerging data, up to 2 additional inhaled dose levels may be added at the discretion of the Sponsor.
This is a phase 1 study to assess the safety, tolerability and pharmacokinetics of AZD8154
following single and multiple ascending dose administration in healthy participants. This
study will have 3 parts (Part 1, Part 2, and Part 3). Part 1 consists of six cohorts, each
consisting of 8 participants. Depending on emerging PK and adverse event (AE) data, 1 to 2
additional inhaled dose levels, within the pre-specified dose range, may be added at the
discretion of the Sponsor. One dose level cohort selected based on emerging data will be
repeated using the same formulation of AZD8154 but with a larger particle size. The selected
cohort (e.g., Cohort 5), referred to as the "Large Particle Size Cohort", will be dosed at
the same dose level with a larger particle size after a minimum washout period of 7 to 14
days between each dose administration.
Small Particle Size Cohorts:
Within each cohort, 6 participants will be randomized to receive an inhaled dose of AZD8154
(small particle size) and 2 participants will be randomized to receive inhaled placebo.
Dosing for each ascending dose cohort will proceed with 2 participants in a sentinel cohort,
such that 1 participant will be randomized to receive placebo and 1 participant will be
randomized to receive AZD8154 (small particle size).
Large Particle Size Cohort:
For the selected Large Particle Size Cohort, the 6 participants that received AZD8154 (small
particle size) will return for a second Treatment Period after a minimum washout period of 7
to 14 days. All 6 participants will receive an inhaled dose of AZD8154 (large particle size),
at the same dose level that they received AZD8154 (small particle size) in Treatment Period
1. The duration of the washout period is based on the predicted half-life of AZD8154 and was
selected to diminish the impact of carry-over effects from the first Treatment Period.
Part 2: Part 2 of this study will be a single cohort. One cohort consisting of 6 participants
will be enrolled into Part 2 of the study. All subjects will receive AZD8154 IV in Treatment
Period 1 and then after washout, receive inhaled AZD8154 (small particle size) in Treatment
Period 2. Intravenous dosing will proceed with 1 participant in a sentinel cohort, no
sentinel dosing will be done in the inhaled dosing period.
Part 3: Three cohorts (MAD Cohort 1 to Cohort 3), each consisting of 8 participants, will
participate in Part 3 of the study. Within each cohort, 6 participants will be randomized to
receive an inhaled dose of AZD8154 and 2 participants will be randomized to receive inhaled
placebo. Dosing for each ascending dose cohort will proceed with 2 participants in a sentinel
cohort, such that 1 participant will be randomized to receive placebo and 1 participant will
be randomized to receive AZD8154. In Part 3, participants will be randomized to receive an
inhaled dose of AZD8154 nebuliser suspension or placebo. Three (3) inhaled dose levels of
AZD8154 that are administered once daily are planned to be investigated. Based upon emerging
PK and safety data in MAD Cohorts 1 to 3, up to 2 additional inhaled dose levels, within the
pre-specified dose range, may also be added at the discretion of the Sponsor.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
||
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|